Cipla stock tanks 8% after USFDA warning over issues at MP unit
ADVERTISEMENT
Shares of pharma giant Cipla Ltd plunged as much as 8% to hit an intraday low of ₹1165.10 apiece on BSE after the United States Food and Drug Administration (USFDA) issued a warning letter to its Madhya Pradesh unit.
The warning letter stressed "data integrity issues" at the company embedded with product complaints and microbial contamination.
Cipla via a regulatory filing says: “The company has received a warning letter dated 17th November, 2023 from USFDA for the routine current Good Manufacturing Practices (cGMP) inspection conducted at our Pithampur manufacturing facility between 6th – 17th February, 2023.”
The warning letter summarises contraventions regarding methods or controls followed at the facility, which do not conform to the prescribed cGMP regulations and contains directional guidance for necessary corrections.
July 2025
In the world’s youngest nation—where over 65% of the population is under 35—India’s future is already being shaped by those bold enough to lead it. From boardrooms to breakout ideas, a new generation of business leaders is rewriting the rules. This year's Fortune India’s 40 Under 40 celebrates these changemakers—icons in the making like Akash Ambani, Kaviya Kalanithi Maran, Shashwat Goenka, Parth Jindal, Aman Mehta, and Devansh Jain—who are not just carrying forward legacies but boldly reimagining them for a new era. Alongside them are first-generation disruptors like Sagar Daryani, scaling Wow! Momo with a vision to take ₹100 momos to 5,000 cities, and Palak Shah, turning the Banarasi weave into a global fashion story with Ekaya Banaras. These are the entrepreneurs turning ambition into scale. And even beyond traditional industry, the entrepreneurial wave is pulling in creative forces—Ranveer Singh, for instance, is shaking up wellness and nutrition with Bold Care and SuperYou, proving that passion, backed by purpose, is the new blueprint for building brands.
“The company will respond to the warning letter within the stipulated timelines and work closely with the USFDA to address the concerns in a holistic and timely manner to ensure sustained compliance. We uphold quality and compliance with utmost importance and remain committed to be compliant with the cGMP quality standards,” it concludes.
The pharma giant says it has received a "warning letter" from the USFDA for routine inspection of good manufacturing practices (GMP) at its Pitampura unit between 6-7th Feb, 2023. The US health regulator mentioned repeated observations for Cipla's facility earlier.
The company's Goa facility is under “Official Action Indicated” status, impacting product approvals from the facility meant for the US market. The US regulator has also asked Cipla to take assistance from third-party consultants to address the issue.
During the July to September quarter of FY24, Cipla's income surged 15% at ₹6,854.47 crore against ₹5,951.49 crore in Q2 FY23. The company's income in Q1 FY24 was at ₹6,465.18 crore.
The company’s profit stood at ₹1,155.37 crore, up 43% compared to ₹797.41 crore reported in the September quarter of last year. In the first six months of the year, the company has reported a total income of ₹13,319.65 crore, over 16.53% higher against its total income of ₹11,430.11 crore in H1 FY23.
The company’s share price closed 8.10% lower at ₹1,168.60 today.
Fortune India is now on WhatsApp! Get the latest updates from the world of business and economy delivered straight to your phone. Subscribe now.